DART and 4 other NPC family foundations continue their support of the SOAR-NPC collaborative effort. SOAR-NPC is in essence a virtual biotech, pharmaceutical enterprise seeking a drug cocktail to arrest the progression of NPC. In September 2009, at the National Institutes of Health, SOAR-NPC’s team was able to initiate its first human trial, and only the second potential therapeutic drug trial ever for NPC. Preliminary results of the trial using N-acetyl cysteine are encouraging with a formal report due out soon. SOAR-NPC’s second human trial is currently being developed and will hopefully start in the winter of 2011. SOAR-NPC started with 3 research institutions working together, but now comprises 5 labs, including the National Institutes of Health’s Chemical Genomic Center.